Additional agents for treatment of CRS include another IL-6 antagonist siltuximab, or alternatively anakinra (IL-1 antagonist), but unfortunately the administration of these agents is associated with an increased risk of opportunistic infections, gastrointestinal perforation and anaphylactic reactions (Driscoll and Bistrian, 2024a). Here, IL6 is linked to congenital rubella syndrome.